Arcus Biosciences Presents Promising Phase 1/1b Trial Data

Arcus Biosciences ( (RCUS) ) has provided an update.

On June 1, 2025, Arcus Biosciences presented updated data from its Phase 1/1b clinical trial ARC-20, involving the combination of casdatifan and cabozantinib for patients with clear cell renal cell carcinoma. The interim analysis, with a data cutoff date of March 14, 2025, showed a confirmed objective response rate of 46% and an acceptable safety profile, indicating potential efficacy and safety for this treatment combination.

The most recent analyst rating on (RCUS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Arcus Biosciences stock, see the RCUS Stock Forecast page.

Spark’s Take on RCUS Stock

According to Spark, TipRanks’ AI Analyst, RCUS is a Neutral.

Arcus Biosciences’ score is driven by strong cash reserves and strategic advancements, notably in the casdatifan program. However, ongoing profitability issues, negative cash flow, and recent revenue declines weigh down the overall score.

To see Spark’s full report on RCUS stock, click here.

More about Arcus Biosciences

Arcus Biosciences, Inc. operates in the biotechnology industry, focusing on the development of innovative cancer therapies. The company is engaged in creating and advancing a portfolio of novel cancer treatments, with a particular emphasis on immuno-oncology and targeted therapies.

Average Trading Volume: 1,154,997

Technical Sentiment Signal: Sell

Current Market Cap: $945.6M

See more insights into RCUS stock on TipRanks’ Stock Analysis page.